These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 34737067)

  • 1. Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing.
    Knipping F; Newby GA; Eide CR; McElroy AN; Nielsen SC; Smith K; Fang Y; Cornu TI; Costa C; Gutierrez-Guerrero A; Bingea SP; Feser CJ; Steinbeck B; Hippen KL; Blazar BR; McCaffrey A; Mussolino C; Verhoeyen E; Tolar J; Liu DR; Osborn MJ
    Mol Ther; 2022 Jan; 30(1):130-144. PubMed ID: 34737067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection.
    Dudek AM; Feist WN; Sasu EJ; Luna SE; Ben-Efraim K; Bak RO; Cepika AM; Porteus MH
    Cell Stem Cell; 2024 Apr; 31(4):499-518.e6. PubMed ID: 38579682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
    Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X
    Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4 is expressed on a heterogeneous subset of hematopoietic progenitors, which persistently harbor CXCR4 and CCR5-tropic HIV proviral genomes in vivo.
    Sebastian NT; Zaikos TD; Terry V; Taschuk F; McNamara LA; Onafuwa-Nuga A; Yucha R; Signer RAJ; Riddell J; Bixby D; Markowitz N; Morrison SJ; Collins KL
    PLoS Pathog; 2017 Jul; 13(7):e1006509. PubMed ID: 28732051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
    Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
    Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4
    Xiao Q; Chen S; Wang Q; Liu Z; Liu S; Deng H; Hou W; Wu D; Xiong Y; Li J; Guo D
    Retrovirology; 2019 Jun; 16(1):15. PubMed ID: 31186067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection.
    Anderson J; Akkina R
    Retrovirology; 2005 Aug; 2():53. PubMed ID: 16109172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome modification of CXCR4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection.
    Wang Q; Chen S; Xiao Q; Liu Z; Liu S; Hou P; Zhou L; Hou W; Ho W; Li C; Wu L; Guo D
    Retrovirology; 2017 Nov; 14(1):51. PubMed ID: 29141633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice.
    Ringpis GE; Shimizu S; Arokium H; Camba-Colón J; Carroll MV; Cortado R; Xie Y; Kim PY; Sahakyan A; Lowe EL; Narukawa M; Kandarian FN; Burke BP; Symonds GP; An DS; Chen IS; Kamata M
    PLoS One; 2012; 7(12):e53492. PubMed ID: 23300932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
    Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
    J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4
    Liu Z; Chen S; Jin X; Wang Q; Yang K; Li C; Xiao Q; Hou P; Liu S; Wu S; Hou W; Xiong Y; Kong C; Zhao X; Wu L; Li C; Sun G; Guo D
    Cell Biosci; 2017; 7():47. PubMed ID: 28904745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.
    Wilen CB; Wang J; Tilton JC; Miller JC; Kim KA; Rebar EJ; Sherrill-Mix SA; Patro SC; Secreto AJ; Jordan AP; Lee G; Kahn J; Aye PP; Bunnell BA; Lackner AA; Hoxie JA; Danet-Desnoyers GA; Bushman FD; Riley JL; Gregory PD; June CH; Holmes MC; Doms RW
    PLoS Pathog; 2011 Apr; 7(4):e1002020. PubMed ID: 21533216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lineage-specific expression of human immunodeficiency virus (HIV) receptor/coreceptors in differentiating hematopoietic precursors: correlation with susceptibility to T- and M-tropic HIV and chemokine-mediated HIV resistance.
    Chelucci C; Casella I; Federico M; Testa U; Macioce G; Pelosi E; Guerriero R; Mariani G; Giampaolo A; Hassan HJ; Peschle C
    Blood; 1999 Sep; 94(5):1590-600. PubMed ID: 10477684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains.
    Huang L; Bosch I; Hofmann W; Sodroski J; Pardee AB
    J Virol; 1998 Nov; 72(11):8952-60. PubMed ID: 9765440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template.
    Sather BD; Romano Ibarra GS; Sommer K; Curinga G; Hale M; Khan IF; Singh S; Song Y; Gwiazda K; Sahni J; Jarjour J; Astrakhan A; Wagner TA; Scharenberg AM; Rawlings DJ
    Sci Transl Med; 2015 Sep; 7(307):307ra156. PubMed ID: 26424571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice.
    Li S; Holguin L; Burnett JC
    Mol Ther Methods Clin Dev; 2022 Mar; 24():321-331. PubMed ID: 35229006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection.
    Hou P; Chen S; Wang S; Yu X; Chen Y; Jiang M; Zhuang K; Ho W; Hou W; Huang J; Guo D
    Sci Rep; 2015 Oct; 5():15577. PubMed ID: 26481100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coreceptor competition for association with CD4 may change the susceptibility of human cells to infection with T-tropic and macrophagetropic isolates of human immunodeficiency virus type 1.
    Lee S; Lapham CK; Chen H; King L; Manischewitz J; Romantseva T; Mostowski H; Stantchev TS; Broder CC; Golding H
    J Virol; 2000 Jun; 74(11):5016-23. PubMed ID: 10799575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
    Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
    Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo.
    Bai J; Gorantla S; Banda N; Cagnon L; Rossi J; Akkina R
    Mol Ther; 2000 Mar; 1(3):244-54. PubMed ID: 10933940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.